Recent Quotes (30 days)

You have no recent quotes
chg | %

GeneNews Ltd  

(Public, TSE:GEN)   Watch this stock  
Find more results for GEN
0.340
0.000 (0.00%)
Dec 2 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.33 - 0.36
52 week 0.01 - 0.57
Open 0.35
Vol / Avg. 159,912.00/384,831.00
Mkt cap 25.90M
P/E     -
Div/yield     -
EPS -0.19
Shares 78.41M
Beta 9.75
Inst. own     -
Nov 11, 2016
Q3 2016 GeneNews Ltd Earnings Release
  

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -2489.14% -1846.70%
Operating margin -2489.15% -1883.91%
EBITD margin - -892.90%
Return on average assets -466.42% -343.37%
Return on average equity - -3136.17%
Employees 4 -
CDP Score - -

Address

445 Apple Creek Blvd Unit 220
MARKHAM, ON L3R 9X7
Canada
+1-905-7392030 (Phone)
+1-905-7392031 (Fax)

Website links

Description

GeneNews Limited is focused on developing and commercializing molecular diagnostic tests for early detection of diseases and for personalized health management, with a primary focus on cancer-related indications. The Company offers Sentinel Principle, which is a platform technology to detect virtually any disease or medical condition from a simple blood sample. The Company also offers ColonSentry, which is a blood-based test for assessing an individual's current risk of having colorectal cancer. The Company operates within the biotechnology, molecular diagnostic and genomic biomarker industry. The Company operates in Canada and the United States, and transacts business primarily with the United States partners and suppliers. The Company's subsidiaries include GeneNews Corporation and GeneNews Inc.

Officers and directors

James R. Howard-Tripp Executive Chairman of the Board
Leslie Auld Chief Financial Officer, Treasurer, Director
Karl Wassmann Executive Vice President - US Corporate Development
Heinrich Dreismann Ph.D. Lead Director
Age: 62
Harry A. Glorikian Independent Director
Garth A. C. MacRae Independent Director
Age: 81
Rory B. Riggs Independent Director
Age: 62